Physician profile
Rufus J Mark
NPI 1992786628
$4,584.23
in general payments reported to CMS, 2019-2025
41 companies · $360 in 2025
The $360 reported for 2025 was more than what a typical Radiation Oncology provider received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,285 · 2020: $136 · 2021: $836 · 2022: $560 · 2023: $300 · 2024: $107 · 2025: $360.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $768.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $767.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bioptics, INC. | $2,284.78 | 2019 | |
| Novartis Pharmaceuticals Corporation | $284.66 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $165.64 | 2021-2025 | Libtayo |
| Amgen INC. | $149.56 | 2020-2023 | Lumakras |
| Astrazeneca Pharmaceuticals LP | $138.92 | 2020-2022 | |
| Abbvie INC. | $134.70 | 2021-2025 | |
| Daiichi Sankyo INC. | $124.88 | 2025 | Enhertu |
| Sumitomo Pharma America, INC. | $93.83 | 2023-2024 | Orgovyx |
| Myriad Genetic Laboratories, INC. | $82.77 | 2021-2023 | Prolaris |
| Eisai INC. | $80.08 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $76.25 | 2021-2023 | |
| Incyte Corporation | $74.35 | 2020-2022 | |
| Janssen Biotech, INC. | $73.74 | 2022-2023 | Erleada |
| Pharmacosmos Therapeutics INC. | $73.36 | 2021 | |
| Myovant Sciences INC. | $59.49 | 2021-2022 |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rufus Mark listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.